Bendamustine Hydrochloride
Showing 1 - 25 of 1,816
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin
Completed
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- +5 more
- gemcitabine hydrochloride
- bendamustine hydrochloride
-
Atlanta, Georgia
- +1 more
Oct 21, 2021
Amyloidosis, Light Chain (AL) Amyloidosis Trial (Bendamustine Hydrochloride, Isatuximab)
Not yet recruiting
- Amyloidosis
- Light Chain (AL) Amyloidosis
- Bendamustine Hydrochloride
- Isatuximab
- (no location specified)
Mar 9, 2022
Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer Trial in Toronto (Pembrolizumab, Bendamustine Hydrochloride)
Recruiting
- Classical Hodgkin Lymphoma
- +2 more
- Pembrolizumab
- Bendamustine Hydrochloride
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Dec 31, 2021
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab
Recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Bendamustine Hydrochloride
- Brentuximab Vedotin
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Dec 17, 2021
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma Trial in Atlanta (Bendamustine, Gemcitabine,
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Bendamustine
- +2 more
-
Atlanta, Georgia
- +1 more
Aug 25, 2021
Non-Hodgkin's Lymphoma Trial in Japan (bendamustine HCl)
Completed
- Non-Hodgkin's Lymphoma
- bendamustine hydrochloride
-
Kanagawa, Japan
- +3 more
Oct 19, 2020
Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma Trial in Winston-Salem (CPI 613, Bendamustine)
Recruiting
- Relapsed T-Cell Lymphoma
- +2 more
- CPI 613
- Bendamustine
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Aug 27, 2021
Indolent Non-hodgkin Lymphoma Trial in München (Obinutuzumab, Bendamustine)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
-
München, Bavaria, GermanyKlinikum der Universität München
Jul 23, 2021
Advanced Solid Tumor Trial in Chuo-ku, Tokyo, Osakasayama (SyB C-0501)
Completed
- Advanced Solid Tumor
- SyB C-0501
-
Chuo-ku, Tokyo, Japan
- +1 more
Apr 25, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (Bendamustine Hydrochloride, Carfilzomib,
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bendamustine Hydrochloride
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 7, 2021
Myeloid Leukemia, Acute, Chronic Myeloid Leukemia, MDS Trial in Saint Petersburg (Bendamustine Hydrochloride, Cyclophosphamid)
Recruiting
- Myeloid Leukemia, Acute
- +3 more
- Bendamustine Hydrochloride
- Cyclophosphamid
-
Saint Petersburg, Russian FederationRM Gorbacheva Research Institute
Apr 4, 2022
Diffuse Large B Cell Lymphoma Trial in Saint-Petersburg (Bendamustine HCl, Gemcitabine 500 mg, Gemcitabine 700 mg)
Completed
- Diffuse Large B Cell Lymphoma
- Bendamustine hydrochloride
- +5 more
-
Saint-Petersburg, Russian FederationFirst Pavlov State Medical University of St. Petersburg
Jun 2, 2021
Lymphoma, Mantle-Cell Trial in Czechia (Polatuzumab vedotin, Bendamustine Hydrochloride, Rituximab)
Not yet recruiting
- Lymphoma, Mantle-Cell
- Polatuzumab vedotin
- +2 more
-
Brno, Czechia
- +6 more
May 28, 2021
Indolent B-Cell Non-Hodgkin's Lymphomas Trial in China (Bendamustine HCl injection)
Completed
- Indolent B-Cell Non-Hodgkin's Lymphomas
- Bendamustine hydrochloride injection
-
Fuzhou, Fujian, China
- +10 more
Sep 25, 2020
Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute, Biphenotypic Acute Leukemia Trial in Saint Petersburg (Fludarabine,
Recruiting
- Leukemia, Acute Lymphoblastic
- +5 more
- Fludarabine
- +5 more
-
Saint Petersburg, Russian FederationRM Gorbacheva Research Institute
Jun 21, 2021
Refractory Multiple Myeloma Trial in United States (bendamustine HCl, lenalidomide, dexamethasone)
Completed
- Refractory Multiple Myeloma
- bendamustine hydrochloride
- +2 more
-
Duarte, California
- +4 more
Feb 10, 2020
Follicular Lymphoma Trial in Houston (Bendamustine, Mitoxantrone, Rituximab)
Terminated
- Follicular Lymphoma
- Bendamustine
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Apr 1, 2020
Symbenda Post-Marketing Surveillance (PMS)
Completed
- Lymphoma, Non-Hodgkin
- +2 more
-
Busan, Korea, Republic of
- +8 more
Jan 25, 2021
Hodgkin's Lymphoma Trial in Saint-Petersburg (Nivolumab, Bendamustine Hydrochloride)
Completed
- Hodgkin's Lymphoma
- Nivolumab
- Bendamustine Hydrochloride
-
Saint-Petersburg, Russian FederationFirst Pavlov State Medical University of St. Petersburg
May 27, 2020
Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is
Completed
- Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate
- Test Product (Bendamustine)
-
Long Beach, California
- +9 more
Jun 2, 2021
Non-Hodgkin's Lymphoma, DLBCL, Mantle Cell Lymphoma Trial in Japan (SyB L-0501, Rituximab)
Completed
- Non-Hodgkin's Lymphoma
- +3 more
- SyB L-0501
- Rituximab
-
Nagoya-city, Aichi, Japan
- +3 more
Jul 1, 2021
AL Amyloidosis Trial in Boston, Detroit, New York (Bendamustine, Dexamethasone)
Completed
- AL Amyloidosis
-
Boston, Massachusetts
- +5 more
Mar 17, 2020
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma Trial in Philadelphia (Bendamustine HCl,
Completed
- Stage I Multiple Myeloma
- +2 more
- Bendamustine hydrochloride
- +2 more
-
Philadelphia, PennsylvaniaThomas Jefferson University
Aug 27, 2019
Chronic Lymphocytic Leukemia Trial in Houston (Lenalidomide, Fludarabine, Rituximab)
Terminated
- Chronic Lymphocytic Leukemia
- Lenalidomide
- +6 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 14, 2020